Thiogenesis Therapeutics, Corp. TTI.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -28.99% | -25.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 59.84% | -46.11% | |||
| Operating Income | -59.84% | 46.11% | |||
| Income Before Tax | -61.89% | 46.49% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -61.89% | 46.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -61.89% | 46.49% | |||
| EBIT | -59.84% | 46.11% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -45.31% | 46.44% | |||
| Normalized Basic EPS | -45.00% | 46.67% | |||
| EPS Diluted | -45.31% | 46.44% | |||
| Normalized Diluted EPS | -45.00% | 46.67% | |||
| Average Basic Shares Outstanding | 11.54% | -0.07% | |||
| Average Diluted Shares Outstanding | 11.54% | -0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||